Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease
11 nov. 2020 02h00 HE
|
Tiziana Life Sciences Plc
First Ever Study with take-home capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody Potential to be a safer and effective alternative to the intravenous immunotherapies currently used...
Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
02 nov. 2020 02h00 HE
|
Tiziana Life Sciences Plc
Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drugTrial facilitated with collaboration of Harvard Medical School and one of the world’s top...
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
27 oct. 2020 12h00 HE
|
Tiziana Life Sciences Plc
NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics...
Tiziana Life Sciences Plc (the "Company") - Result of General Meeting
02 oct. 2020 07h00 HE
|
Tiziana Life Sciences Plc
LONDON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- At the General Meeting of the Company (Nasdaq: TLSA / AIM: TILS) held at 11.00 a.m. on 2 October 2020, both of the resolutions were duly passed. The...
Tiziana Life Sciences Interview to Air on Bloomberg International on The RedChip Money Report
25 sept. 2020 02h00 HE
|
Tiziana Life Sciences Plc
LONDON and NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics...
Tiziana Life Sciences plc: Publication of Research Note
21 sept. 2020 09h51 HE
|
Tiziana Life Sciences Plc
LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst...
Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil
17 sept. 2020 02h00 HE
|
Tiziana Life Sciences Plc
Nasal Administration of Foralumab is a potentially transformative approach for treating patients with Covid-19 NEW YORK and LONDON, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc...
Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, Accustem Sciences
16 sept. 2020 06h00 HE
|
Tiziana Life Sciences Plc
NEW YORK and LONDON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted...
Tiziana Life Sciences Plc ("Tiziana" or the "Company") - Demerger of StemPrintER and Distribution in Specie
16 sept. 2020 02h00 HE
|
Tiziana Life Sciences Plc
LONDON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Plc (LSE: TILS, NASDAQ: TLSA) a biotechnology company focussed on innovative therapeutics for oncology, inflammation and infectious...
Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement
28 août 2020 05h30 HE
|
Tiziana Life Sciences Plc
NEW YORK and LONDON, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted...